Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care Vincent Launay-VacherJean-Baptiste ReyMikael Daouphars Review 04 March 2008 Pages: 903 - 909
Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand Henriette GourdeauJames B. McAlpinePierre Falardeau Original Article 11 July 2007 Pages: 911 - 921
IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells Jon PattersonVito J. PalombellaEmmanuel Normant Original Article 12 July 2007 Pages: 923 - 932
Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin Srinivasan YuvarajVummidi Giridhar PremkumarPanchanatham Sachdanandam Original Article 01 August 2007 Pages: 933 - 941
Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells Rui WangFang LinHui-Zhong Zhang Original Article 26 July 2007 Pages: 943 - 952
A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity Fanying MengXiaohong CaiCharles P. Hart Original Article 18 July 2007 Pages: 953 - 963
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression Andrea RoccaGiuseppe VialeMarco Colleoni Original Article 18 July 2007 Pages: 965 - 971
New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin Hirokazu KawanoShintaro KomabaYasufumi Kaneda Original Article 26 July 2007 Pages: 973 - 978
Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells Jianli ChenMahesha AdikariHenry Simpkins Original Article 28 July 2007 Pages: 979 - 987
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group Norikazu MasudaTetsuya TaguchiKinki Breast Cancer Study Group (KBCSG) Original Article 20 July 2007 Pages: 989 - 995
The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors Jianjun LuJohn K. JacksonHelen M. Burt Original Article 15 August 2007 Pages: 997 - 1005
Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line Teresa L. SerafimPaulo J. OliveiraJon Holy Original Article 28 July 2007 Pages: 1007 - 1018
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma E. Gabriela ChioreanTomislav DragovichPatrick J. Loehrer Original Article 28 July 2007 Pages: 1019 - 1026
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples Erwin R. BoghaertKiran M. KhandkeNitin K. Damle Original Article 01 August 2007 Pages: 1027 - 1035
Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats Pengfei SongFei MaCharles R. Yates Original Article 01 September 2007 Pages: 1037 - 1044
Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth Shirley Cruz LioJessica JohnsonMark L. Richards Original Article 10 August 2007 Pages: 1045 - 1058
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study Michael D. PradosW. K. A. YungJohn Kuhn Clinical Trial Report 11 August 2007 Pages: 1059 - 1067
A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma Robert J. AmatoMuhammad Khan Clinical Trial Report 14 August 2007 Pages: 1069 - 1073
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor F. J. P. HoebersD. PluimA. C. Begg Short Communication Open access 18 July 2007 Pages: 1075 - 1081
Dermatitis after suspected imatinib–levothyroxine interaction in a patient with gastrointestinal stromal tumor Evangelos CholongitasChrysoula PipiliMaria Dasenaki Letter to the Editor 07 August 2007 Pages: 1083 - 1084